Department of Urology, Urologic Cancer, Research Institute and Hospital of National Cancer Center, Goyang, Korea.
Department of Pathology, Hospital of National Cancer Center, Goyang, Korea.
Cancer Res Treat. 2020 Jan;52(1):128-138. doi: 10.4143/crt.2019.119. Epub 2019 Jun 19.
The purpose of this study was to identify prognostic tissue markers for several survival outcomes after radical nephroureterectomy among patients with upper urinary tract urothelial carcinoma using tissue microarray and immunohistochemistry.
Retrospectively, data of 162 non-metastatic patients with upper urinary tract urothelial carcinoma after radical nephroureterectomy between 2004 and 2016 were reviewed to determine intravesical recurrence-free survival (IVRFS), disease-free survival (DFS), and overall survival (OS). The expression of 27 tissue markers on a tissue microarray of radical nephroureterectomy samples and prognostic values of clinicopathological parameters were evaluated using immunohistochemistry and Cox proportional hazard models after adjusting for significant prognostic clinicopathological variables. The expression of all tissue markers was categorized into a binary group with continuous H-scores (0-300).
Median follow-up was 53.4 months (range, 3.6 to 176.5 months); and, 58 (35.8%), 48 (29.6%), and 19 (11.7%) bladder recurrence, disease progression, and all cause death, respectively, were identified. After adjusting for significant clinicopathological factors including intravesical instillation for bladder recurrence-free survival, pathologic T category and intravesical instillation for disease progression-free survival , and pathologic T category for OS (p < 0.05), IVRFS was associated with epithelial cadherin (hazard ratio [HR], 0.49), epidermal growth factor receptor/erythroblastosis oncogene B (c-erb) (HR, 2.59), and retinoblastoma protein loss (HR, 1.85); DFS was associated with cyclin D1 (HR, 2.16) and high-molecular-weight cytokeratin (HR, 0.42); OS was associated with E-cadherin (HR, 0.34) and programmed cell death 1 ligand (HR, 13.42) (p < 0.05).
Several significant tissue markers were associated with survival outcomes in upper urinary tract urothelial carcinoma patients treated with radical nephroureterectomy.
本研究旨在使用组织微阵列和免疫组织化学技术,鉴定接受根治性肾输尿管切除术的上尿路上皮癌患者的几种生存结局的预后组织标志物。
回顾性分析了 2004 年至 2016 年间接受根治性肾输尿管切除术的 162 例非转移性上尿路上皮癌患者的数据,以确定膀胱内无复发生存(IVRFS)、无病生存(DFS)和总生存(OS)。使用免疫组织化学和 Cox 比例风险模型,评估组织微阵列中 27 种组织标志物的表达,并在调整显著的临床病理预后变量后,评估组织微阵列中 27 种组织标志物的表达及其与临床病理参数的相关性。所有组织标志物的表达均采用连续 H 评分(0-300)的二分法进行分类。
中位随访时间为 53.4 个月(范围:3.6 至 176.5 个月);分别有 58(35.8%)、48(29.6%)和 19(11.7%)例患者发生膀胱复发、疾病进展和全因死亡。在调整包括膀胱无复发生存的膀胱内灌注、疾病无进展生存的病理 T 分期和膀胱内灌注以及 OS 的病理 T 分期在内的显著临床病理因素后(p <0.05),IVRFS 与上皮钙黏蛋白(HR,0.49)、表皮生长因子受体/红细胞生成素 B(c-erb)(HR,2.59)和视网膜母细胞瘤蛋白缺失(HR,1.85)相关;DFS 与细胞周期蛋白 D1(HR,2.16)和高分子量细胞角蛋白(HR,0.42)相关;OS 与 E-钙黏蛋白(HR,0.34)和程序性细胞死亡 1 配体(HR,13.42)相关(p <0.05)。
在接受根治性肾输尿管切除术治疗的上尿路上皮癌患者中,几种显著的组织标志物与生存结局相关。